AVTX — Avalo Therapeutics Share News
0.000.00%
Last trade - 00:00- $399.54m
- $1.27m
- $0.06m
U.S. RESEARCH ROUNDUP- Constellation Brands, Northern Trust, Roper Technologies
U.S. STOCKS ON THE MOVE-Copper miners, Benitec Biopharma, SL Green
U.S. STOCKS ON THE MOVE-Wolfspeed, Papa John, Chart Industries
Avalo Therapeutics falls as asthma therapy fails to meet goal in mid-stage study
U.S. STOCKS ON THE MOVE-Vertex Energy, Adamis Pharma, Gold miners
Avalo Therapeutics falls as asthma therapy fails to meet goal in mid-stage study
U.S. RESEARCH ROUNDUP-Albemarle, Cable One, Southwest Airlines
Brief: Avalo Therapeutics Inc Enters Into Sales Agreement With Oppenheimer & Co.
Avalo Therapeutics Inc expected to post a loss of 97 cents a share - Earnings Preview
Brief: Avalo Therapeutics Inc Delivered Written Notice To Cantor Fitzgerald & Co. & RBC Capital Markets, Llc To Terminate Sales Agreement
Brief: Avalo Therapeutics Inc Files For Mixed Shelf Of Up To $375 Million – SEC Filing
Avalo Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Avalo Reports 2022 Financial Results And Provides Business Updates
Avalo Therapeutics Inc expected to post a loss of 73 cents a share - Earnings Preview
Brief: Avalo Therapeutics, Inc. Announces Pricing Of $15 Million Public Offering Of Common Stock And Warrants
Brief: Avalo Therapeutics Inc Announces Proposed Public Offering Of Common Stock And Warrants
Avalo Therapeutics up on enrollment completion for asthma treatment trial
Brief: Avalo Completes Enrollment Of 80 Patients In Phase 2 Asthma Study
U.S. RESEARCH ROUNDUP-Calithera Biosciences, Haynes International, Lumos Pharma